Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis
Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis - Prospective Trial NeoSTROBE
University Hospital Ostrava
260 participants
May 1, 2025
INTERVENTIONAL
Conditions
Summary
This multicentre proof-of-concept study, involving 4 centers, aims to establish the value of fractionated neoadjuvant stereotactic radiotherapy (NaSRT) as a new treatment paradigm for brain metastases (BM) in the frame of the Czech neurooncology network. Most relevant studies published to date used single-fraction radiotherapy and dealt with the inherent bias related to their retrospective nature. The researchers aim to increase the level of evidence for this treatment paradigm together with other similar ongoing studies.
Eligibility
Inclusion Criteria6
- Age ≥ 18 years
- Karnofsky Performance Status ≥ 60
- Histologically verified primary cancer disease
- MRI findings indicating BM
- Target BM indicated for surgical resection and any other metastases suitable for radical SRT.
- Target BM between 1 cm and 7 cm at the longest diameter on T1 post-contrast MR imaging
Exclusion Criteria7
- Confirmed hematological malignity
- Small-cell (lung) carcinoma
- Peracute condition requiring immediate neurosurgical intervention
- History of whole-brain radiotherapy (WBRT)
- History of stereotactic radiotherapy to a target brain metastasis
- Pregnancy
- Inability to perform surgical resection of the target BM within 7 days after NaSRT
Interventions
Neoadjuvant Stereotactic Radiotherapy (NaSRT) gives radiotherapy before surgery from many different angles around the body. The beams meet at the tumor. This means the tumor receives a high dose of radiation and the tissues around it receive a much lower dose. This lowers the risk of side effects.
Postoperative Stereotactic Radiotherapy (SRT) gives radiotherapy after surgery from many different angles around the body. The beams meet at the tumor. This means the tumor receives a high dose of radiation and the tissues around it receive a much lower dose. This lowers the risk of side effects.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06933199